The investigators aimed to investigate hepassocin levels in patients with polycystic ovary syndrome (PCOS). There are 3 groups aged between 18 and 35 years as non-obese healthy women, non-obese women with PCOS, and obese women (BMI\>30) with PCOS.
Hepassocin, also known as Fibrinogen-like-protein or hepatocyte-derived fibrinogen-related protein 1, is a new marker for obesity and insulin resistance. In hepatic injury, it protects liver cells and promotes regeneration. High levels of hepassocin was shown to be independently associated with HOMA-IR and diabetes. Since insulin resistance is known to be seen in patients with PCOS, it may be expected that hepassocin levels may be higher in this group of patients.
Study Type
OBSERVATIONAL
Enrollment
90
hepassocin levels in polycystic ovary syndrome
Gaziosmanpasa Taksim Education and Research Hospital
Istanbul, Turkey (Türkiye)
Hepassocin levels in patients with polycystic ovary syndrome
hepassocin levels should be increased in polycyctic ovary syndrome due to its relation with insulin resistance.
Time frame: January 2020-March 2020
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.